This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:physicians [03.03.2018] – [Resources for physicians] +Ref. to Bactrim and K in some sallieq | home:physicians [12.18.2018] – [Resources for physicians] sallieq | ||
---|---|---|---|
Line 2: | Line 2: | ||
====== Resources for physicians | ====== Resources for physicians | ||
- | < | + | < |
The Marshall Protocol (MP) is the name given to a therapy devised by Professor Trevor Marshall. Based on the pathogenesis Marshall has proposed for chronic inflammatory disease, the MP is aimed at targeting bacteria, fungi, viruses, and other microbes that appear to interact to cause chronic inflammatory diseases. | The Marshall Protocol (MP) is the name given to a therapy devised by Professor Trevor Marshall. Based on the pathogenesis Marshall has proposed for chronic inflammatory disease, the MP is aimed at targeting bacteria, fungi, viruses, and other microbes that appear to interact to cause chronic inflammatory diseases. | ||
Line 20: | Line 20: | ||
The MP uses multiple daily dosing of olmesartan medoxomil (Benicar, Olmecip, Olmetec) to re-activate the Vitamin D Nuclear Receptor, dislodging bacterial ligands in the process. This drug was developed as an Angiotensin II Receptor Blocker (ARB) but it has multiple actions in the human body when dosed as defined by Marshall. In addition to immunostimulation via the VDR, Olmesartan also reduces inflammatory cytokine production by inhibiting the NF kappa-B transcription pathway. This inhibits, among other things, the release of TNF-alpha, helping to protect the organs from effects of excessive inflammation. | The MP uses multiple daily dosing of olmesartan medoxomil (Benicar, Olmecip, Olmetec) to re-activate the Vitamin D Nuclear Receptor, dislodging bacterial ligands in the process. This drug was developed as an Angiotensin II Receptor Blocker (ARB) but it has multiple actions in the human body when dosed as defined by Marshall. In addition to immunostimulation via the VDR, Olmesartan also reduces inflammatory cytokine production by inhibiting the NF kappa-B transcription pathway. This inhibits, among other things, the release of TNF-alpha, helping to protect the organs from effects of excessive inflammation. | ||
- | Additionally, | + | Additionally, |
| | ||
Line 32: | Line 32: | ||
<note warning> | <note warning> | ||
- | =====Recent presentations===== | ||
- | |||
- | < | ||
- | |||
- | Trevor Marshall and the rest of the Autoimmunity Research Foundation research team have been active in publishing papers and making presentations before learned bodies. | ||
- | |||
- | Marshall' | ||
- | |||
- | ^Presenter(s) | ||
- | |Marshall TG |2016 September|Predictive, | ||
- | |Marshall TG |2016 April |10th Congress on Autoimmunity |[[.: | ||
- | |Marshall TG |2015 September | ||
- | |Marshall TG |2015 May |Preventive Medicine 2015 |[[.: | ||
- | |Marshall TG |2012 June | ||
- | |Lindseth IA |2012 May |8th International Congress on Autoimmunity |[[.: | ||
- | |Marshall TG |2012 May |8th International Congress on Autoimmunity |[[.: | ||
- | |Goetze-Pelka R |2011 November | ||
- | |Marshall TG |2011 May | ||
=====Physicians' | =====Physicians' | ||
Line 56: | Line 38: | ||
{{section>: | {{section>: | ||
- | |||
- | |||
- | |||
Line 70: | Line 49: | ||
< | < | ||
+ | |||
==== Contact Trevor Marshall directly ==== | ==== Contact Trevor Marshall directly ==== | ||
Line 75: | Line 55: | ||
To ensure success, physicians are asked to encourage their patients to carefully study this Knowledge Base. This site provides additional instructions, | To ensure success, physicians are asked to encourage their patients to carefully study this Knowledge Base. This site provides additional instructions, | ||
- | =====Read more===== | ||
- | {{topic> | + | ===== Representative presentations===== |
- | + | < | |
+ | Trevor Marshall and the rest of the Autoimmunity Research Foundation research team have been active in publishing papers and making presentations before learned bodies. | ||
+ | This material is provided in order to give a more detailed description of the Marshall Pathogenesis and Protocol. | ||
+ | |||
+ | ^Presenter(s) | ||
+ | |Marshall TG |2016 September|Predictive, | ||
+ | |Marshall TG |2016 April |10th Congress on Autoimmunity |[[.: | ||
+ | |Marshall TG |2015 September | ||
+ | |Marshall TG |2015 May |Preventive Medicine 2015 |[[.: | ||
+ | |Marshall TG |2012 June | ||
+ | |Lindseth IA |2012 May |8th International Congress on Autoimmunity |[[.: | ||
+ | |Marshall TG |2012 May |8th International Congress on Autoimmunity |[[.: | ||
+ | |Goetze-Pelka R |2011 November | ||
+ | |Marshall TG |2011 May | ||
+ | =====Read more===== | ||
+ | |||
+ | {{topic> | ||
+ | |||
+ | |||
===== Notes and comments ===== | ===== Notes and comments ===== | ||